
Novo Nordisk says Victoza lowers risk of heart attacks in diabetes patients
pharmafile | June 14, 2016 | News story | Manufacturing and Production, Research and Development | Novo Nordisk, Victoza, drug trial, type 2 diabetes
Danish diabetes drugmaker giant Novo Nordisk (NYSE: NVO) on Tuesday said a large study showed its Victoza (liraglutide) reduced the risk of heart attack in combination with standard therapy for type 2 diabetes patients.
Mads Krogsgaard Thomsen, chief science officer of Novo Nordisk, said: “We are very excited by the Leader trial results that demonstrate a significant reduction in major cardiovascular events among type 2 diabetes patients treated with Victoza, including all-cause death. For us, this marks the beginning of a new era where our R&D focus will go beyond glucose control.”
Victoza is the only approved GLP-1 receptor agonist to demonstrate a superior reduction of major CV events vs placebo, both on top of standard of care, in a cardiovascular outcomes trial.
John Buse, chairman of the trial steering committee, said: “These findings are exciting, as it demonstrates that Victoza can improve outcomes beyond glucose reduction and weight loss by helping to avoid cardiovascular complications and death in people with type 2 diabetes.
“Type 2 diabetes treatments that can also reduce cardiovascular risk are important since cardiovascular disease is the leading cause of death worldwide in this patient population,” he added.
Anjali Shukla
Related Content

FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …

BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …

Ciloa secures €6.5m from French government to advance obesity and T2 diabetes therapy
French biotech company, Ciloa, has received €6.5m in funding through France 2030 to advance its …






